Closed System Transfer Device Market Size is Anticipated to Hit US$ 1,620.6 Mn by 2027

The closed system transfer device market size is expected to reach USD 1,620.6 million by 2027. It is anticipated to grow with a healthy CAGR of 20.6% from 2021 to 2027.

In 2022, the closed system transfer device market study provides crucial information on market share, market size, growth rate analysis Y-O-Y, production, consumption, and sales analysis for the forecast period 2021 to 2027. The report contains 150+ pages with detailed analysis.

Closed System Drug Transfer Device (CSTD) is employed for safe drug transmission and to curb transmission of environmental impurities into the arrangement and leakage or transmission of vapor absorptions or hazardous drug outside the arrangement. Uncontrolled inflow and outflow of preparations and impurities are prevented by CSTDs and solution’s drug grade is conserved along with contributing protection to the healthcare workers that take care of the drug solution. CSTDs have two design types: those that work by way of a physical barrier and those that use air-cleaning expertise. Working exposure while compounding and controlling hazardous preparations is linked to a variety of negative health significances. Both the design types of CSTDs prevent the discharge of hazardous preparations into the workplace. Many harmful drugs are frequently employed in patient treatment procedures. They can comprise of antineoplastic drugs for chemotherapy procedures, new monoclonal antibodies, and antibiotics. Healthcare experts, including nurses, pharmacists, and veterinarians, can be vulnerable to hazardous drug through skin contact, inhalation, sharps and needle stick injuries, or unintentional hand-to-mouth assimilation.

Growth Factors:

Factors such as growing prevalence of cancer and rising need for monitoring compliance for harmless handling of damaging drugs are driving the growth of closed system transfer device market. Antineoplastic drugs, also known as anticancer drugs, are life-saving for cancer patient. However, these drugs can also be detrimental to the health of the medical professionals. This can occur if the drugs escape during compounding, rebuilding or delivery to patients. At the oncology center, the pharmacy specialists prepare all quantities of chemotherapy under the direction of the expert pharmacist. The CSTDs (Closed system drug transfers devices) are very well known for efficiency at decreasing surface adulteration and contact of healthcare workers after execution. CSTDs are thus necessary for such medicinal preparations. Growing prevalence of cancer all over the world has heavily amplified the demand for the closed system drug transfer devices. Globally, cancer prevalence rate has amplified to make it the second chief cause of demise after cardiovascular disease.

Hazardous drugs, specifically the subclasses of antineoplastic medications, have been designated as the highest chemical hazard existing in the health field and one of the furthermost dangerous chemical agents ever made. Establishments focused on industrial safety, such as the Occupational and Safety and Health Administration (OSHA), Joint Commission, and the Pan American Health Organization (PAHO) are offering increasing consideration to recommendations and tactics for improving protection regarding harmful drugs.

Report Scope of the Clinical Trials Market

COVID-19 Impact:

The industrial report mentions the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The closed system transfer device report proficiently explains the resulting factors and concerns of manufacturers. Researchers have also well-explained how the producers and providers will tackle the ongoing epidemic and the key strategies to be adopted post-pandemic for turning their businesses back to normal.

Regional Analysis:

The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2019, North America dominated the global market with a market share of more than 42%. U.S. represented the highest share in the North American region primarily due to presence of leading market players and high awareness regarding drug safety. Furthermore, early adoption of latest healthcare technologies also contributed to the high market share of the United States.

Europe was the second important market chiefly due to presence of latest healthcare infrastructure and high investment in research and development. The presence of skilled researchers in the European region is also expected to boost the demand for closed system transfer device market in the near future. Asia Pacific is anticipated to grow at the maximum CAGR of around 18% in the forecast period due to high incidence of cancer. Latin America and the African and Middle Eastern region will display noticeable growth.

Key Players:

The closed system transfer device market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the prominent players in the closed system transfer device market include:

• Baxter International Inc.
• Becton, Dickinson, and Company
• CodanMedizinischeGeräte GmbH & Co Kg
• ICU Medical, Inc.
• Yukon Medical
• Braun Melsungen
• Equashield
• Teva Pharmaceutical Industries Ltd.
• Victus, Inc.
• Corvida Medical

Market Segmentation

By Type

• Needleless Systems
• Membrane-to-Membrane Systems

By Closing Mechanism

• Color-To-Color Alignment Systems
• Push-To-Turn Systems
• Click-To-Lock Systems
• Luer-Lock Systems

By Component

• Syringe Safety Devices
• Vial Access Devices
• Accessories
• Bag/Line Access Devices

By End User

• Clinics & Oncology Centers
• Hospitals
• Others

Regional Segmentation

• North America (U.S. and Canada)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Find More Press Releases at https://www.globenewswire.com/en/search/organization/Precedence%2520Research

Frequently Asked Questions?

• What is the total market value?
• What will be the growth in 2027?
• What are the key trends in the market?
• What are the major players in closed system transfer device markets?
• What are the key growth strategies of industry players?
• Which region would offer a higher growth?
• What are the countries included in the rest of the word segments?
• How can I get report sample?

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Regenerative Medicine Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Regenerative Medicine Market

5.1. Covid-19: Regenerative Medicine Industry Impact
5.2. Regenerative Medicine Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Regenerative Medicine Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Regenerative Medicine Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Regenerative Medicine Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of cancer
6.1.1.2. Growing need for regulatory compliance for safe handling of harmful drugs
6.1.2. Market Restraints
6.1.2.1. High cost systems
6.1.3. Market Opportunities
6.1.3.1. Rising adoption of closed system transfer devices for transferring hazardous drugs
6.1.3.2. Increasing use of CSTDs in emerging markets

Chapter 7. Global Regenerative Medicine Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Regenerative Medicine Market Revenue by Market Players (2016 -2019)
7.1.1.2. Regenerative Medicine Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Regenerative Medicine Market, By Product

8.1. Regenerative Medicine Market, by Product, 2016-2027
8.1.1. Needleless Systems
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Membrane-to-Membrane Systems
8.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global Regenerative Medicine Market, By Closing Mechanism

9.1. Regenerative Medicine Market, by Application, 2016-2027
9.1.1. Color-To-Color Alignment Systems
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Push-To-Turn Systems
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Click-To-Lock Systems
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Luer-Lock Systems
9.1.4.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global Regenerative Medicine Market, By Component

10.1. Regenerative Medicine Market, by Application, 2016-2027
10.1.1. Syringe Safety Devices
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Vial Access Devices
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Accessories
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Bag/Line Access Devices
10.1.4.1. Market Revenue and Forecast (2016-2027)

Chapter 11. Global Regenerative Medicine Market, By End User

11.1. Regenerative Medicine Market, by Application, 2016-2027
11.1.1. Clinics & Oncology Centers
11.1.1.1. Market Revenue and Forecast (2016-2027)
11.1.2. Hospitals
11.1.2.1. Market Revenue and Forecast (2016-2027)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2016-2027)

Chapter 12. Global Regenerative Medicine Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue Forecast by Type (2016-2027)
12.1.2. Market Revenue Forecast by Closing Mechanism (2016-2027)
12.1.3. Market Revenue Forecast by Component (2016-2027)
12.1.4. Market Revenue Forecast by End User (2016-2027)
12.1.5. U.S
12.1.5.1. Market Revenue Forecast (2016-2027)
12.1.6. Canada
12.1.6.1. Market Revenue Forecast (2016-2027)
12.2. Europe
12.2.1. Market Revenue Forecast by Type (2016-2027)
12.2.2. Market Revenue Forecast by Closing Mechanism (2016-2027)
12.2.3. Market Revenue Forecast by Component (2016-2027)
12.2.4. Market Revenue Forecast by End User (2016-2027)
12.2.5. UK
12.2.5.1. Market Revenue Forecast (2016-2027)
12.2.6. Germany
12.2.6.1. Market Revenue Forecast (2016-2027)
12.2.7. France
12.2.7.1. Market Revenue Forecast (2016-2027)
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast (2016-2027)
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by Type (2016-2027)
12.3.2. Market Revenue Forecast by Closing Mechanism (2016-2027)
12.3.3. Market Revenue Forecast by Component (2016-2027)
12.3.4. Market Revenue Forecast by End User (2016-2027)
12.3.5. China
12.3.5.1. Market Revenue Forecast (2016-2027)
12.3.6. India
12.3.6.1. Market Revenue Forecast (2016-2027)
12.3.7. Japan
12.3.7.1. Market Revenue Forecast (2016-2027)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast (2016-2027)
12.4. LATAM
12.4.1. Market Revenue Forecast by Type (2016-2027)
12.4.2. Market Revenue Forecast by Closing Mechanism (2016-2027)
12.4.3. Market Revenue Forecast by Component (2016-2027)
12.4.4. Market Revenue Forecast by End User (2016-2027)
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast (2016-2027)
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast (2016-2027)
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by Type (2016-2027)
12.5.2. Market Revenue Forecast by Closing Mechanism (2016-2027)
12.5.3. Market Revenue Forecast by Component (2016-2027)
12.5.4. Market Revenue Forecast by End User (2016-2027)
12.5.5. GCC
12.5.5.1. Market Revenue Forecast (2016-2027)
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast (2016-2027)
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast (2016-2027)
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast (2016-2027)

Chapter 13. Company Profiles

13.1. Baxter International Inc.
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. ProductPortfolio Analysis
13.1.2.1. ProductDetails, Specification, Application
13.1.3. Revenue, Price, and Gross Margin (2015-2020)
13.1.4. Recent Developments and Strategies
13.2. Becton, Dickinson, and Company
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Application
13.2.3. Revenue, Price, and Gross Margin (2015-2020)
13.2.4. Recent Developments and Strategies
13.3. CodanMedizinischeGeräte GmbH & Co Kg
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Application
13.3.3. Revenue, Price, and Gross Margin (2015-2020)
13.3.4. Recent Developments and Strategies
13.4. ICU Medical, Inc.
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Application
13.4.3. Revenue, Price, and Gross Margin (2015-2020)
13.4.4. Recent Developments and Strategies
13.5. Yukon Medical
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Application
13.5.3. Revenue, Price, and Gross Margin (2015-2020)
13.5.4. Recent Developments and Strategies
13.6. B. Braun Melsungen
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Application
13.6.3. Revenue, Price, and Gross Margin (2015-2020)
13.6.4. Recent Developments and Strategies
13.7. Equashield
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Application
13.7.3. Revenue, Price, and Gross Margin (2015-2020)
13.7.4. Recent Developments and Strategies
13.8. Teva Pharmaceutical Industries Ltd.
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Application
13.8.3. Revenue, Price, and Gross Margin (2015-2020)
13.8.4. Recent Developments and Strategies
13.9. Victus, Inc.
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Application
13.9.3. Revenue, Price, and Gross Margin (2015-2020)
13.9.4. Recent Developments and Strategies
13.10. Corvida Medical
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Application
13.10.3. Revenue, Price, and Gross Margin (2015-2020)
13.10.4. Recent Developments and Strategies

Chapter 14. Appendix

14.1. About Us
14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333